Filing Details
- Accession Number:
- 0001562180-23-000872
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-02 20:06:13
- Reporting Period:
- 2023-01-31
- Accepted Time:
- 2023-02-02 20:06:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1603756 | Axonics Inc. | AXNX | Surgical & Medical Instruments & Apparatus (3841) | 454744083 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1756240 | Karen Noblett | 26 Technology Drive Irvine CA 92618 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-01-31 | 5,000 | $0.00 | 36,599 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2023-01-31 | 10,250 | $0.00 | 46,849 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-31 | 2,167 | $61.17 | 44,682 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-01-31 | 1,536 | $61.12 | 43,146 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-01 | 136 | $60.43 | 43,010 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-01 | 795 | $61.02 | 42,215 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance-Based Restricted Stock Units | Acquisiton | 2023-01-31 | 15,000 | $0.00 | 15,000 | $0.00 |
| Common Stock | Performance-Based Restricted Stock Units | Acquisiton | 2023-01-31 | 5,000 | $0.00 | 5,000 | $0.00 |
| Common Stock | Performance-Based Restricted Stock Units | Disposition | 2023-01-31 | 4,250 | $0.00 | 4,250 | $0.00 |
| Common Stock | Performance-Based Restricted Stock Units | Disposition | 2023-01-31 | 6,000 | $0.00 | 6,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,000 | 2024-01-31 | No | 4 | A | Direct | |
| 5,000 | 2025-01-31 | No | 4 | A | Direct | |
| 0 | 2023-01-31 | No | 4 | M | Direct | |
| 0 | 2023-01-31 | No | 4 | M | Direct |
Footnotes
- Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.
- This transaction was executed in multiple trades at prices ranging from $60.78 to $61.595. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $60.78 to $61.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $59.85 to $60.845. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $60.85 to $61.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.
- The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.
- Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.
- The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.
Billionaire Hedge Funds
